These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 7548699)

  • 1. Stopping a clinical trial very early based on unplanned interim analyses: a group sequential approach.
    Emerson SS
    Biometrics; 1995 Sep; 51(3):1152-62. PubMed ID: 7548699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
    Edelman MJ; Meyers FJ; Houston J; Lauder I
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-68-S15-71. PubMed ID: 9346226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biochemical modulation in the treatment of advanced cancer: a study of combined leucovorin, fluorouracil, and iododeoxyuridine.
    Marshall JL; Richmond E; DeLap RJ
    Clin Cancer Res; 1996 Sep; 2(9):1475-80. PubMed ID: 9816323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.).
    Gebbia V; Majello E; Testa A; Pezzella G; Giuseppe S; Giotta F; Riccardi F; Fortunato S; Colucci G; Gebbia N
    Cancer; 1996 Sep; 78(6):1300-7. PubMed ID: 8826954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I and pharmacokinetic study of weekly 5-fluorouracil administered with granulocyte-macrophage colony-stimulating factor and high-dose leucovorin: a potential role for growth factor as mucosal protectant.
    Meropol NJ; Rustum YM; Creaven PJ; Blumenson LE; Frank C
    Cancer Invest; 1999; 17(1):1-9. PubMed ID: 10999043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interim analyses for randomized clinical trials: the group sequential approach.
    Pocock SJ
    Biometrics; 1982 Mar; 38(1):153-62. PubMed ID: 7082757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
    Lewis RJ; Lipsky AM; Berry DA
    Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Termination rules in therapeutic trials. Application of sequential methods in 2 clinical trials in hematology].
    Bénichou J; Lepage E; Chastang C
    Nouv Rev Fr Hematol (1978); 1987; 29(1):87-91. PubMed ID: 3473443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interstitial lung diseases in patients treated with oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX).
    Jung KH; Kil SY; Choi IK; Seo JH; Shin C; Kim YS; Kim JH
    Int J Tuberc Lung Dis; 2006 Oct; 10(10):1181-2. PubMed ID: 17044215
    [No Abstract]   [Full Text] [Related]  

  • 11. Factorial designs for randomized clinical trials.
    Byar DP; Piantadosi S
    Cancer Treat Rep; 1985 Oct; 69(10):1055-63. PubMed ID: 4042085
    [No Abstract]   [Full Text] [Related]  

  • 12. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
    Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
    Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and analysis of group sequential logrank tests in maximum duration versus information trials.
    Kim K; Boucher H; Tsiatis AA
    Biometrics; 1995 Sep; 51(3):988-1000. PubMed ID: 7548714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Systemic palliative chemotherapy with 5-fluorouracil and leucovorin in disseminated colorectal cancer].
    Wiboltt K; Raskov HH
    Ugeskr Laeger; 1999 Jun; 161(25):3827-32. PubMed ID: 10412300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interim analyses in 2 x 2 crossover trials.
    Cook RJ
    Biometrics; 1995 Sep; 51(3):932-45. PubMed ID: 7548709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical trial designs based on sequential conditional probability ratio tests and reverse stochastic curtailing.
    Tan M; Xiong X; Kutner MH
    Biometrics; 1998 Jun; 54(2):682-95. PubMed ID: 9629648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Spanish experience with high-dose infusional 5-fluorouracil (5-FU) in colorectal cancer. The Spanish Cooperative Group For Gastrointestinal Tumor Therapy (TTD).
    Aranda E; Cervantes A; Carrato A; Antón-Torres A; Massutí T; Fernández-Martos C; Díaz-Rubio E
    J Infus Chemother; 1996; 6(3):118-22. PubMed ID: 9229321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequentist evaluation of group sequential clinical trial designs.
    Emerson SS; Kittelson JM; Gillen DL
    Stat Med; 2007 Dec; 26(28):5047-80. PubMed ID: 17573678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase III evaluation of octreotide versus chemotherapy with 5-fluorouracil or 5-fluorouracil plus leucovorin in advanced exocrine pancreatic cancer: a North Central Cancer Treatment Group study.
    Burch PA; Block M; Schroeder G; Kugler JW; Sargent DJ; Braich TA; Mailliard JA; Michalak JC; Hatfield AK; Wright K; Kuross SA
    Clin Cancer Res; 2000 Sep; 6(9):3486-92. PubMed ID: 10999733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Guidelines for monitoring efficacy and toxicity responses in clinical trials.
    Cook RJ; Farewell VT
    Biometrics; 1994 Dec; 50(4):1146-52. PubMed ID: 7786995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.